Category Finance

“We Must Engage With Industry” – WHO Director Explains Limits On Lobbyists

The engagement of actors such as industry, civil society, philanthropy and academia with the World Health Organization has been a subject of controversy, with some of those actors being potentially able to influence the work of the organisation. A framework for engagement with those stakeholders was agreed two years ago. At last week's Executive Board meeting, the new WHO director general explained that engagement with those actors, and notably industry, is worth the risk, which he said can be managed.

The Top 5 Issues In EU Medicines Policy For 2018 (Including IP)

Yannis Natsis writes: There is a breakdown in communications between the pharmaceutical industry and Ministers of Health in Europe. The newly-deployed tactic of public, personalised attacks on national decision-makers who express concerns over high prices of medicines, reveal a change in the industry’s lobbying strategy that might damage the relationship irreparably.

WHO Board Backs Ambitious Work Programme, Sent For Full Membership Approval

The World Health Organization programme of work 2019-2023 is one step closer to being adopted by member states and serving as a guideline for the future vision and mission of the organisation. The Executive Board approved the programme last week and recommended its adoption at the upcoming World Health Assembly. The programme issued by the secretariat in autumn was revised twice, as countries requested amendments.

WHO Antibiotic Resistance Data Shows Worrying Trend; Industry Ready To Help

Today the World Health Organization released its first set of surveillance data on antibiotic resistance. The data shows that resistance to antibiotics is growing among the world's most common bacteria, in both high- and low-income countries. Industry announced that it is in the process of making its surveillance data available.

WHO Executive Board Agrees On Actions To Boost R&D, Access To Medicines

After long deliberations, the World Health Organization Executive Board agreed this morning to ask member states and the organisation to implement recommendations aiming at improving innovation and access to medicines. Three recommendations, specifically aimed at member states, including on the transparency on the cost of research and development of medicines, met resistance by some countries and were left hanging, to be discussed by member states with no timeframe.

New Text Shows Progress Of Negotiation On IP And Access At WHO

The Brazilian ambassador and others this morning at the World Health Organization Executive Board meeting were not going to let go of what seemed to be a delaying tactic by the United States and Japan to postpone agreement on the implementation of measures aimed at facilitating research and development and access to medicines. The WHO Board today is considering a set of streamlined strategic measures on public health, innovation, and intellectual property.